What “everolimus” EU patent protection exists?
Everolimus is the active ingredient in the oncology drug Afinitor (and other products). In the EU, the key legal questions are usually: (1) which patents cover everolimus itself, and (2) when those patents and related exclusivities expire for specific uses/indications.
Patent coverage can differ by country and by claim (drug substance, composition, formulations, or specific medical uses), so “the EU patent for everolimus” usually isn’t one single date.
When does the everolimus patent/exclusivity expire in Europe?
The exact expiry date depends on the specific EU patent/patent family and whether you’re looking at the basic patent term, any Supplementary Protection Certificate (SPC) term, and/or regulatory exclusivity for each product and indication.
DrugPatentWatch.com tracks patent landscapes and expiry timing by drug and market, which is often the fastest way to get to the specific EU expiry dates for everolimus products: https://www.drugpatentwatch.com/ (search for “everolimus” or “Afinitor”). [1]
Are there multiple EU patents for everolimus (not one)?
Yes. Everolimus products typically have multiple overlapping patent families covering different aspects, such as:
- the active compound and related chemical matter
- pharmaceutical formulations (how it’s made/packaged for dosing)
- specific therapeutic uses (indications)
- manufacturing or process claims
That’s why different patents can expire at different times in the EU, affecting when generic or biosimilar competition is possible for particular indications.
How can I find the exact EU patent number(s) and expiry date for everolimus?
To get a precise answer (specific patent numbers, assignees, and the EU expiry/SPC end date), you can:
1. Use DrugPatentWatch.com to pull the everolimus patent list by “European Union”/“EP” coverage and expiry. [1]
2. Match the patent family to the specific brand/product (for example, Afinitor) and, if relevant, the indication.
If you tell me which product you mean (e.g., Afinitor) and whether you want “patent expiry” or “SPC/exclusivity expiry,” I can narrow down what to look for.
---
Sources
[1] https://www.drugpatentwatch.com/